Skip to main content
Erschienen in: Surgery Today 9/2017

15.02.2017 | Original Article

Role of pulmonary metastasectomy in colorectal cancer in the era of modern multidisciplinary therapy

verfasst von: Ryu Kanzaki, Masayoshi Inoue, Toru Kimura, Tomohiro Kawamura, Soichiro Funaki, Yasushi Shintani, Masato Minami, Ichiro Takemasa, Tsunekazu Mizushima, Masaki Mori, Meinoshin Okumura

Erschienen in: Surgery Today | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To clarify the role of pulmonary metastasectomy in colorectal cancer in the era of modern multidisciplinary therapy.

Methods

The characteristics and outcomes of the patients who underwent pulmonary metastasectomy for colorectal cancer through 2002 (n = 26) and from 2003 (n = 68) were compared.

Results

The patients treated from 2003 had a smaller tumor size and more frequently had a history of extra-pulmonary relapses than did those treated through 2002. There was a significant improvement in the 5-year overall survival (42.0% vs. 73.1%, p = 0.03) but not the 5-year relapse-free survival (41.4% vs. 37.5%, p = 0.85) after pulmonary metastasectomy from 2003. The rate of patients who received local therapy with curative intent after the first pulmonary metastasectomy was significantly higher in patients treated from 2003 than in those treated through 2002 [4/13, (31%) vs. 25/39 (64%), p = 0.04]. The survival after relapse after the first pulmonary metastasectomy was significantly longer in patients treated from 2003 than in those treated through 2002 (median survival time: 14 vs. 47 months).

Conclusions

Pulmonary metastasectomy for colorectal cancer remains an important treatment option in the sense that it can achieve a good relapse-free survival.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siearl RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed Torre LA, Bray F, Siearl RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Zurück zum Zitat Kobayashi H, Mochizuki H, Morita T, Kotake K, Teramoto T, Kameoka S, et al. Timing of relapse and outcome after curative resection for colorectal cancer: a Japanese multicenter study. Dig Surg. 2009;26:249–55.CrossRefPubMed Kobayashi H, Mochizuki H, Morita T, Kotake K, Teramoto T, Kameoka S, et al. Timing of relapse and outcome after curative resection for colorectal cancer: a Japanese multicenter study. Dig Surg. 2009;26:249–55.CrossRefPubMed
3.
Zurück zum Zitat Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.CrossRefPubMedPubMedCentral Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Higashiyama M, Kodama K, Higaki N, Takami K, Murata K, Kameyama M, et al. Surgery for pulmonary metastases from colorectal cancer: the importance of prethoracotomy serum carcinoembryonic antigen as an indicator of prognosis. Jpn J Thorac Cardiovasc Surg. 2003;51:289–96.CrossRefPubMed Higashiyama M, Kodama K, Higaki N, Takami K, Murata K, Kameyama M, et al. Surgery for pulmonary metastases from colorectal cancer: the importance of prethoracotomy serum carcinoembryonic antigen as an indicator of prognosis. Jpn J Thorac Cardiovasc Surg. 2003;51:289–96.CrossRefPubMed
5.
Zurück zum Zitat Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg. 2004;78:238–44.CrossRefPubMed Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg. 2004;78:238–44.CrossRefPubMed
6.
Zurück zum Zitat Higashiyama M, Tokunaga T, Nakagiri T, Ishida D, Kuno H, Okami J. Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection. Gen Thorac Cardiovasc Surg. 2015;63:320–30.CrossRefPubMed Higashiyama M, Tokunaga T, Nakagiri T, Ishida D, Kuno H, Okami J. Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection. Gen Thorac Cardiovasc Surg. 2015;63:320–30.CrossRefPubMed
7.
Zurück zum Zitat Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H, et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg. 2013;257:1059–64.CrossRefPubMed Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H, et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg. 2013;257:1059–64.CrossRefPubMed
8.
Zurück zum Zitat Kanzaki R, Higashiyama M, Oda K, Fujiwara A, Tokunaga T, Maeda J, et al. Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg. 2011;202:419–26.CrossRefPubMed Kanzaki R, Higashiyama M, Oda K, Fujiwara A, Tokunaga T, Maeda J, et al. Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg. 2011;202:419–26.CrossRefPubMed
9.
Zurück zum Zitat Nakajima J. Pulmonary metastasis: rationale for local treatments and techniques. Gen Thorac Cardiovasc Surg. 2010;58:445–51.CrossRefPubMed Nakajima J. Pulmonary metastasis: rationale for local treatments and techniques. Gen Thorac Cardiovasc Surg. 2010;58:445–51.CrossRefPubMed
10.
Zurück zum Zitat Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66:83–95.CrossRefPubMed Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66:83–95.CrossRefPubMed
11.
Zurück zum Zitat Kitajima K, Murakami K, Yamasaki E, Domeki Y, Tsubaki M, Sunagawa M, et al. Performance of intearly-period grouprated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with intearly-period grouprated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:1388–96.CrossRefPubMed Kitajima K, Murakami K, Yamasaki E, Domeki Y, Tsubaki M, Sunagawa M, et al. Performance of intearly-period grouprated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with intearly-period grouprated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:1388–96.CrossRefPubMed
12.
Zurück zum Zitat Ogawa H, Uemura M, Nishimura J, Hata T, Ikenaga M, Takemasa I, et al. Preoperative chemoradiation followed by extensive pelvic surgery improved the outcome of posterior invasive locally recurrent rectal cancer without deteriorating surgical morbidities: a retrospective, single-institution analysis. Ann Surg Oncol. 2015;22:4325–34.CrossRefPubMed Ogawa H, Uemura M, Nishimura J, Hata T, Ikenaga M, Takemasa I, et al. Preoperative chemoradiation followed by extensive pelvic surgery improved the outcome of posterior invasive locally recurrent rectal cancer without deteriorating surgical morbidities: a retrospective, single-institution analysis. Ann Surg Oncol. 2015;22:4325–34.CrossRefPubMed
13.
Zurück zum Zitat Hasegawa H, Ninomiya M, Honbou T, Hamatsu T, Kudo K, Ushijima C, et al. A case of long-term survival by combined modality therapy for liver and pulmonary metastasis of rectal cancer. Jpn J Cancer Chemother. 2011;38:2310–2. Hasegawa H, Ninomiya M, Honbou T, Hamatsu T, Kudo K, Ushijima C, et al. A case of long-term survival by combined modality therapy for liver and pulmonary metastasis of rectal cancer. Jpn J Cancer Chemother. 2011;38:2310–2.
14.
Zurück zum Zitat de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.CrossRefPubMed de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.CrossRefPubMed
15.
Zurück zum Zitat Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, et al. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. Hepatogastroenterology. 2009;56:1346–53.PubMed Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, et al. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. Hepatogastroenterology. 2009;56:1346–53.PubMed
16.
Zurück zum Zitat Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, et al. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol. 2013;43:1080–6.CrossRefPubMedPubMedCentral Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, et al. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol. 2013;43:1080–6.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Bamba Y, Itabashi M, Kameoka S. Management of local recurrence of colorectal cancer: the role of PET/CT. Abdom Imaging. 2011;36:322–6.CrossRefPubMed Bamba Y, Itabashi M, Kameoka S. Management of local recurrence of colorectal cancer: the role of PET/CT. Abdom Imaging. 2011;36:322–6.CrossRefPubMed
18.
Zurück zum Zitat Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol. 2010;194:766–71.CrossRefPubMed Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol. 2010;194:766–71.CrossRefPubMed
19.
20.
Zurück zum Zitat Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today. 2013;43:1088–94.CrossRefPubMed Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today. 2013;43:1088–94.CrossRefPubMed
21.
Zurück zum Zitat Stattner S, Primavesi F, Yip VS, Jones RP, Ofner D, Malik HZ, et al. Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience. Surg Today. 2015;45:407–15.CrossRefPubMed Stattner S, Primavesi F, Yip VS, Jones RP, Ofner D, Malik HZ, et al. Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience. Surg Today. 2015;45:407–15.CrossRefPubMed
22.
Zurück zum Zitat Lippitz B, Lindquist C, Paddick I, Peterson D, O’Neill K, Beaney R. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev. 2014;40:48–59.CrossRefPubMed Lippitz B, Lindquist C, Paddick I, Peterson D, O’Neill K, Beaney R. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev. 2014;40:48–59.CrossRefPubMed
23.
Zurück zum Zitat Yokota M, Kobayashi A, Nomura S, Nishizawa Y, Ito M, Nagai K, et al. Patterns and treatment of recurrence following pulmonary resection for colorectal metastases. World J Surg. 2015;39:1758–66.CrossRefPubMed Yokota M, Kobayashi A, Nomura S, Nishizawa Y, Ito M, Nagai K, et al. Patterns and treatment of recurrence following pulmonary resection for colorectal metastases. World J Surg. 2015;39:1758–66.CrossRefPubMed
24.
Zurück zum Zitat Imaizumi K, Koshiishi H, Nakata T, Matsuyama T, Hirano T, Okuno K, et al. Three cases of resected pulmonary metastasis from colorectal cancer after preoperative chemotherapy. Jpn J Cancer Chemother. 2014;41:2056–8. Imaizumi K, Koshiishi H, Nakata T, Matsuyama T, Hirano T, Okuno K, et al. Three cases of resected pulmonary metastasis from colorectal cancer after preoperative chemotherapy. Jpn J Cancer Chemother. 2014;41:2056–8.
25.
Zurück zum Zitat Kondo R, Hamanaka K, Kawakami S, Eguchi T, Saito G, Hyougotani A, et al. Benefits of video-assisted thoracic surgery for repeated pulmonary metastasectomy. Gen Thorac Cardiovasc Surg. 2010;58:516–23.CrossRefPubMed Kondo R, Hamanaka K, Kawakami S, Eguchi T, Saito G, Hyougotani A, et al. Benefits of video-assisted thoracic surgery for repeated pulmonary metastasectomy. Gen Thorac Cardiovasc Surg. 2010;58:516–23.CrossRefPubMed
Metadaten
Titel
Role of pulmonary metastasectomy in colorectal cancer in the era of modern multidisciplinary therapy
verfasst von
Ryu Kanzaki
Masayoshi Inoue
Toru Kimura
Tomohiro Kawamura
Soichiro Funaki
Yasushi Shintani
Masato Minami
Ichiro Takemasa
Tsunekazu Mizushima
Masaki Mori
Meinoshin Okumura
Publikationsdatum
15.02.2017
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 9/2017
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-017-1478-x

Weitere Artikel der Ausgabe 9/2017

Surgery Today 9/2017 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.